Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia have?
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia has 323 citations in the OpenAlex counts ScholarIQ stores.
When was Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia published?
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia has 2020 year in the ScholarIQ index.
What is the open-access status of Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia?
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia has bronze oa status in the ScholarIQ index.
What is the DOI of Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia?
The DOI for Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia is on the source record.
What is the PMID of Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia?
The PMID for Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia is on the source record.
What is the OpenAlex record for Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia?
The OpenAlex for Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia is on the source record.